Perfil dos usuários de um CAPS infanto - juvenil em um município da Paraíba.

Abstract

About 20% of the world population of children and adolescents experience or have experienced some mental disorder. Mental disorders in childhood and adolescence have a strong social and family impact and may be associated with psychiatric and social problems throughout life. In Brazil, health services must offer the population mental health care aimed at disease prevention, health promotion and rehabilitation. Being the Psychosocial Care Centers (CAPS), a specialized place for the treatment of people with psychological distress, severe mental disorder and who use crack, alcohol and other drugs. Objective: To analyze the profile of patients treated and registered at CAPS for children in an interior of the state of Paraíba. Methods: Descriptive study, using data from patients' medical records to analyze the variables: sex, age, education, origin of referral, use of psychotropic drugs, therapeutic groups and most prevalent diagnoses from a population selected for convenience. Results: 105 medical records were consulted, in which it was identified that most users were male (75%), aged between 3 and 19 years. They attended school (93%). As for the origin of the referrals, it was found that 23% entered the service by spontaneous demand, 17% by the UBS and 34% by other services. The ICD-10 code appeared in most of the medical records (75%). The most prevalent disorders were: pervasive developmental disorders, hyperkinetic disorders and childhood autism. The use of medication was present in 61% of the medical records analyzed. There was a higher prevalence of prescriptions for the classes of Atypical Antipsychotics and Anticonvulsants. The most prescribed drugs were risperidone and carbamazepine, respectively. The use of more than one drug was observed in 42% of the cases. It was possible to verify the participation in therapeutic groups in most cases (93%). Conclusion: The use of medication implies the need for clinical monitoring actions of the user, in order to promote the effectiveness of the therapy, identification of adverse events and better adherence to treatment. In this context, the inclusion or greater participation of the pharmacist in the CAPS is recommended as a way of offering a pharmacotherapeutic follow-up of the treatment in order to improve the user's quality of life.